Merck & Co Stock Price, News & Analysis

Merck (NYSE: MRK) will host a virtual investor event on April 5, 2022, at 10:00am ET, after the American College of Cardiology Scientific Session 2022. The event will provide insights into Merck’s extensive cardiovascular portfolio and pipeline. Cardiovascular disease remains a significant global health issue, claiming approximately 18 million lives annually. Merck highlights its commitment to innovation and research in this field, aiming to improve patient outcomes. For more details, visit Merck's investor relations website.

Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-716 trial, which evaluated KEYTRUDA as adjuvant treatment for patients with resected stage IIB and IIC melanoma. The trial met its key secondary endpoint of distant metastasis-free survival (DMFS), showing a statistically significant improvement compared to placebo. Additionally, KEYTRUDA demonstrated improved recurrence-free survival (RFS) at previous analyses. No new safety concerns were noted, reinforcing its efficacy as an adjuvant therapy. Full results will be presented at an upcoming medical meeting.

Merck (NYSE: MRK) has announced that Caroline Litchfield, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on Monday, March 7, at 12:50 p.m. ET. This virtual event invites investors, analysts, media, and the public to listen via a provided link. With over 130 years in the industry, Merck continues to focus on developing medicines and vaccines to combat various diseases globally.

Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022, at 9:10 a.m. EST. A live video webcast of the event will be accessible for investors, analysts, media, and the public. Organon, a global healthcare company formed from a Merck spin-off, focuses on women's health with a diverse portfolio of over 60 products. The company aims to innovate and partner with biopharmaceutical innovators, leveraging its significant global presence.

Merck (NYSE: MRK) announced the retirement of Dr. Julie L. Gerberding, chief patient officer, effective May 2022. Dr. Gerberding will join the Foundation for the National Institutes of Health as CEO on May 16. During her 12-year tenure at Merck, she significantly enhanced the company's commitment to patient care and sustainability, contributing to its environmental, social, and governance strategies. CEO Robert M. Davis praised her leadership and impact on both the company and global health initiatives.

Organon (NYSE: OGN) has appointed Meghan Rivera as the new US Managing Director, bringing over 20 years of experience in biopharmaceuticals and digital therapeutics. Ms. Rivera will lead the company's US Commercial Operations team, consisting of 400 staff, aiming to capitalize on growth in women's health, biosimilars, and established brands. Previously, she held key roles at Akili Interactive and AMAG Pharmaceuticals. Organon, a company spun off from Merck (NYSE: MRK), has a strong portfolio of over 60 products focused on women's health, supported by solid cash flows for innovation and growth.

Merck (NYSE: MRK) and Eisai have received approval from Japan's Ministry of Health for the combination of KEYTRUDA, an anti-PD-1 therapy, and LENVIMA, a receptor tyrosine kinase inhibitor, for treating radically unresectable or metastatic renal cell carcinoma (RCC). This approval follows promising results from the CLEAR/KEYNOTE-581 trial, where the combination showed a 61% reduction in the risk of disease progression or death, with a median progression-free survival of 23.9 months compared to 9.2 months for sunitinib.

This is KEYTRUDA plus LENVIMA's second approval in Japan, previously approved for advanced endometrial carcinoma.

Merck (NYSE: MRK) is hosting a virtual Investor Event at 10:00 a.m. EST to discuss its Environmental, Social & Governance (ESG) strategy. The company’s ESG priorities focus on Access to Health, Employees, Environmental Sustainability, and Ethics & Values, aligning with the United Nations 2030 Sustainable Development Goals. Presentations will cover how these initiatives are integral to Merck’s long-term business value. A Q&A session will follow the management's remarks, open to investors, analysts, media, and the public.

Organon reported 2021 revenue of $6.3 billion, a 3% decline from 2020, driven by losses in Established Brands. However, Nexplanon and biosimilars saw double-digit growth. Q4 revenue decreased by 1%, with a significant 46% drop in net income from continuing operations year-on-year. The company anticipates 2022 revenue between $6.1 billion and $6.4 billion, with adjusted EBITDA margins projected at 34%-36%. A quarterly dividend of $0.28 was declared, payable on March 17, 2022.